VPS4 Antibody

What are the main types of VPS4 antibodies available for research applications?

VPS4 antibodies are available in several formats, including mouse monoclonal and rabbit polyclonal antibodies. The mouse monoclonal VPS4 Antibody (E-8) detects both VPS4A and VPS4B of mouse, rat, and human origin . Rabbit polyclonal antibodies specific to VPS4A are also available, such as the 14272-1-AP antibody that reacts with human, mouse, and rat samples . These antibodies come in various conjugated forms including unconjugated, HRP-conjugated, FITC-conjugated, PE-conjugated, and Alexa Fluor-conjugated versions, offering flexibility for different experimental designs .

Which applications can VPS4 antibodies be reliably used for?

VPS4 antibodies can be used for multiple applications including:

• Western blotting (WB): Typically at dilutions of 1:1000-1:6000 for polyclonal antibodies

• Immunoprecipitation (IP): Usually requiring 2-4 μg for lysates from human cells

• Immunofluorescence (IF): Effective for tracking VPS4 localization in cellular contexts

• Enzyme-linked immunosorbent assay (ELISA): For quantitative detection of VPS4 proteins

• Immunohistochemistry (IHC): At dilutions of 1:50-1:500 for tissue sections

• Confocal microscopy: Particularly useful for co-localization studies with other cellular components

How do I determine the optimal working concentration for VPS4 antibodies in my experiments?

Determining the optimal working concentration requires empirical testing through titration experiments. Begin with the manufacturer's recommended dilution ranges (e.g., 1:1000-1:6000 for Western blot ). Perform a dilution series spanning this range to identify the concentration that provides the best signal-to-noise ratio. The optimal concentration may vary depending on your specific sample type and experimental conditions. For immunohistochemistry applications, antigen retrieval methods can significantly impact antibody performance, with TE buffer pH 9.0 being recommended for some VPS4A antibodies, while citrate buffer pH 6.0 may serve as an alternative .

How should I design experiments to study VPS4's role in viral infection using antibodies?

When designing experiments to study VPS4's role in viral infection, consider a multi-faceted approach:

• Expression manipulation: Establish cell lines stably expressing dominant-negative mutant forms of VPS4 (e.g., VPS4-E233Q that allows ATP binding but blocks hydrolysis) .

• Infection assays: Compare infection efficiency between normal and VPS4-mutant cells using luciferase reporter-positive viral pseudovirions (PsVs). Normalize infection to 100% in control cells to calculate the reduction in infection efficiency upon VPS4 mutant expression .

• Co-immunoprecipitation studies: To detect interactions between viral components and VPS4, immunoprecipitate VPS4 using appropriate antibodies (e.g., anti-GFP for GFP-tagged VPS4) and detect co-immunoprecipitating viral proteins by western blotting .

• Immunofluorescence analysis: Grow cells on poly-L-lysine coverslips, induce VPS4 expression if using inducible systems, infect with viral particles, fix cells with paraformaldehyde, and stain using appropriate antibodies against both VPS4 and viral components .

• Direct interaction assays: Use purified wild-type VPS4 and domain-deletion mutants (e.g., MIT domain deletion) together with purified viral proteins to assess direct interactions in vitro .

What controls are essential when using VPS4 antibodies in co-immunoprecipitation experiments?

In co-immunoprecipitation experiments with VPS4 antibodies, include the following essential controls:

• Input control: Analyze a small portion of the pre-immunoprecipitated lysate to confirm the presence of both VPS4 and potential interacting partners.

• Negative antibody control: Perform parallel immunoprecipitation with an isotype-matched irrelevant antibody to detect non-specific binding.

• Protein interaction negative control: Include a known non-interacting protein control to establish the specificity of detected interactions.

• Domain deletion mutants: When studying specific interaction domains (such as the MIT domain of VPS4), compare wild-type VPS4 with domain deletion mutants to validate binding specificity .

• Reciprocal co-IP: If possible, perform the reverse immunoprecipitation (pull down the suspected interacting partner and blot for VPS4) to confirm the interaction.

How can I optimize western blot protocols specifically for VPS4 detection?

To optimize western blot protocols for VPS4 detection:

• Sample preparation: Use RIPA buffer for cell lysis, ensuring complete extraction of membrane-associated VPS4 proteins .

• Protein loading: Load equal amounts of total cell protein extract as verified by housekeeping protein controls .

• Gel percentage selection: Use 10-12% polyacrylamide gels for optimal resolution of VPS4 proteins, which have a molecular weight of approximately 48-55 kDa .

• Transfer conditions: Optimize transfer time and voltage for proteins in this molecular weight range.

• Blocking: Use 5% non-fat dry milk or BSA in TBST for blocking (BSA is preferred if using phospho-specific antibodies).

• Antibody dilution: Start with a dilution of 1:1000-1:6000 for primary antibody incubation . For mouse monoclonal antibodies like VPS4 Antibody (E-8), a 1:1000 dilution is often effective .

• Washing steps: Perform thorough washing with TBST between antibody incubations to reduce background.

• Detection method: Choose an appropriate detection method based on expected protein abundance; chemiluminescence is suitable for most applications, while fluorescent secondary antibodies can provide better quantitative analysis.

How can I use VPS4 antibodies to investigate the structural dynamics of VPS4 oligomerization?

Investigating VPS4 oligomerization with antibodies requires combining antibody-based techniques with structural biology approaches:

• Conformation-specific antibodies: Develop or select antibodies that specifically recognize different oligomeric states (monomers, dimers, or dodecamers) of VPS4.

• Crosslinking immunoprecipitation: Use chemical crosslinkers to stabilize VPS4 oligomers before immunoprecipitation with VPS4 antibodies, then analyze by western blotting under non-reducing conditions.

• Immunofluorescence microscopy with oligomerization mutants: Compare the localization patterns of wild-type VPS4 with mutants that specifically inhibit dimerization, dodecamerization, or both .

• Proximity ligation assays: Utilize this technique to visualize and quantify VPS4 self-interactions in situ, using VPS4-specific antibodies.

• Correlative light and electron microscopy: Combine immunofluorescence of VPS4 with electron microscopy to visualize oligomeric structures at high resolution.

• Single-molecule analysis: Use fluorescently labeled antibody fragments to track VPS4 oligomerization dynamics in living cells through super-resolution microscopy.

The crystallographic studies have revealed that VPS4 can form different oligomeric states, including a catalytically active dodecamer and a catalytically inactive dimer. These oligomers are stabilized by extensive interactions between the large and small AAA ATPase domains of adjacent VPS4 subunits .

What approaches can resolve contradictory results when studying VPS4A versus VPS4B functionality using antibodies?

When faced with contradictory results between VPS4A and VPS4B studies:

• Isoform-specific antibodies: Ensure you are using antibodies that specifically distinguish between VPS4A and VPS4B. Validate antibody specificity using overexpression and knockdown controls for each isoform.

• Cellular context considerations: The relative importance of VPS4A versus VPS4B may vary across cell types. Systematically compare their expression levels and localization patterns in your specific cell models.

• Functional redundancy analysis: Design experiments to test whether VPS4A and VPS4B have redundant functions by:

  • Single vs. double knockdown/knockout approaches

  • Rescue experiments with the alternate isoform

  • Domain-swapping experiments between VPS4A and VPS4B

• Interaction network mapping: Use immunoprecipitation with isoform-specific antibodies followed by mass spectrometry to identify unique versus shared interacting partners of VPS4A and VPS4B.

• Structural comparison: Compare the structural features of VPS4A and VPS4B using available crystal structures, such as the human VPS4B and yeast Vps4 structures .

How can VPS4 antibodies be utilized to study its role in multivesicular body (MVB) formation and viral budding mechanisms?

To study VPS4's role in MVB formation and viral budding:

• Subcellular fractionation with immunoblotting: Isolate MVB-enriched fractions and analyze VPS4 distribution using specific antibodies. Compare fractions from normal cells versus cells expressing dominant-negative VPS4 mutants.

• Immunoelectron microscopy: Use gold-labeled VPS4 antibodies to visualize VPS4 localization at MVBs and viral budding sites at ultrastructural resolution.

• Live-cell imaging: Combine fluorescently tagged viruses with immunofluorescence for endogenous VPS4 to track their dynamic association during viral budding.

• Co-localization analysis: Perform immunofluorescence to assess co-localization between VPS4 and:

  • Other ESCRT components

  • Viral structural proteins (e.g., HIV-1 Gag or HPV L1/L2)

  • MVB markers

• ESCRT-III disassembly assays: Use in vitro assays with purified components to measure VPS4's ability to disassemble ESCRT-III polymers, using antibodies to track complex formation and disassembly.

• Mutational analysis: Test the effects of mutations in key VPS4 domains (e.g., the Pore Loop 2 arginine residues R241 and R251) on viral budding efficiency, as these residues have been shown to be required for efficient HIV-1 budding .

• Temporal analysis of recruitment: Use time-resolved immunofluorescence to determine the sequence of recruitment of VPS4 relative to other factors during MVB formation and viral budding.

What are the most common reasons for non-specific binding when using VPS4 antibodies, and how can these issues be resolved?

Common reasons for non-specific binding and their solutions:

• Antibody quality issues:

  • Use antibodies validated by the manufacturer for your specific application

  • Consider affinity-purified antibodies like the VPS4A antibody (14272-1-AP) from Proteintech

• Inadequate blocking:

  • Increase blocking time or concentration

  • Try alternative blocking agents (BSA, normal serum, commercial blocking buffers)

• Suboptimal antibody concentration:

  • Perform a titration series to identify the optimal concentration

  • For Western blot, start with manufacturer recommendations (e.g., 1:1000-1:6000)

• Cross-reactivity with related proteins:

  • Use isoform-specific antibodies when studying VPS4A versus VPS4B

  • Validate specificity using overexpression and knockdown controls

• Sample preparation issues:

  • Ensure complete cell lysis with appropriate buffers (RIPA is often effective)

  • Include protease inhibitors to prevent degradation

  • Use fresh samples when possible

• Detection system sensitivity:

  • Optimize exposure time for Western blots

  • Consider more sensitive detection systems for low-abundance targets

How can I validate the specificity of VPS4 antibodies for my particular experimental system?

To validate VPS4 antibody specificity:

• Genetic controls:

  • Test antibody reactivity in VPS4 knockout/knockdown cells

  • Compare with cells overexpressing VPS4

  • Use cells expressing dominant-negative VPS4 mutants as positive controls

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide

  • Compare staining/binding with and without peptide competition

• Multiple antibody validation:

  • Use multiple antibodies targeting different epitopes of VPS4

  • Compare staining patterns across antibodies

• Recombinant protein controls:

  • Run purified recombinant VPS4 alongside your samples in Western blots

  • Use tag-based detection as an orthogonal method

• Cross-species reactivity:

  • Verify antibody performance across species if working with non-human models

  • The VPS4 Antibody (E-8) has been validated for mouse, rat, and human samples

• Application-specific validation:

  • For immunohistochemistry, include appropriate tissue controls

  • For immunoprecipitation, verify enrichment by Western blot

What strategies can improve detection sensitivity when studying low-abundance VPS4 complexes?

To improve detection of low-abundance VPS4 complexes:

• Signal amplification methods:

  • Use tyramide signal amplification (TSA) for immunofluorescence

  • Consider biotin-streptavidin amplification systems

• Concentration and enrichment:

  • Perform immunoprecipitation to concentrate VPS4 before analysis

  • Use subcellular fractionation to enrich for VPS4-containing compartments

• Optimized antibody selection:

  • Choose high-affinity antibodies

  • Consider using conjugated primary antibodies (HRP, FITC, PE, or Alexa Fluor conjugates)

• Enhanced detection systems:

  • Use highly sensitive ECL substrates for Western blotting

  • Employ quantum dot-conjugated secondary antibodies for immunofluorescence

• Specialized imaging techniques:

  • Apply deconvolution to immunofluorescence images

  • Use super-resolution microscopy techniques (STED, PALM, STORM)

• Cross-linking approaches:

  • Stabilize transient complexes with chemical cross-linkers before immunoprecipitation

  • Use proximity ligation assays to detect protein-protein interactions in situ

• Optimized sample preparation:

  • Include phosphatase inhibitors if studying phosphorylation-dependent interactions

  • Use detergents suitable for membrane protein complexes

  • Minimize sample processing steps to reduce protein loss

How can I design experiments to investigate the role of VPS4 in the HIV-1 and HPV life cycles using antibodies?

To investigate VPS4's role in viral life cycles:

• Temporal mapping of VPS4-virus interactions:

  • Infect cells with viruses and harvest at different time points

  • Immunoprecipitate VPS4 and blot for viral proteins to determine when interactions occur

  • For HPV, interactions between VPS4B and the viral L1/L2 proteins have been demonstrated

• Domain-specific interaction analysis:

  • Use purified VPS4 and its domain mutants (e.g., MIT domain deletion) with viral proteins

  • Direct interaction assays have shown that HPV-16 L2 interacts directly with VPS4B, while L1 shows weaker interaction

  • Both interactions depend on the MIT domain of VPS4B

• Functional studies with dominant-negative VPS4:

  • Express VPS4-E233Q mutant (blocks ATP hydrolysis) in cells

  • Assess effects on viral entry, uncoating, replication, and budding

  • For HPV, loss of VPS4 ATPase activity causes delayed capsid uncoating and defective endocytic transport

• Co-localization during infection:

  • Perform immunofluorescence using antibodies against VPS4 and viral proteins

  • For HPV infections, stain for total L1 using CAMVIR-1 antibody or uncoating-specific 33L1-7 antibody

  • Quantify co-localization events at different stages of infection

• Mutational analysis of key functional regions:

  • Target conserved motifs like Pore Loop 2 with its arginine residues (R241, R251)

  • These residues are required for efficient HIV-1 budding

What considerations are important when studying VPS4 phosphorylation states or other post-translational modifications?

When studying VPS4 post-translational modifications:

• Modification-specific antibodies:

  • Use antibodies that specifically recognize phosphorylated or otherwise modified VPS4

  • Validate specificity using phosphatase treatment or mutation of modification sites

• Phosphorylation site analysis:

  • Consider that VPS4 regulation during cytokinesis involves CHMP4C phosphorylation status

  • VPS4 is retained at the midbody by ZFYVE19/ANCHR and CHMP4C until dephosphorylation of CHMP4C leads to its release

• Sample preparation considerations:

  • Include phosphatase inhibitors in lysis buffers

  • Consider using specialized extraction conditions for different modifications

  • Use mild detergents that preserve protein interactions

• Kinase/phosphatase inhibitors:

  • Treat cells with specific inhibitors to modulate modification states

  • Monitor effects on VPS4 localization and function

• Mass spectrometry approach:

  • Immunoprecipitate VPS4 and analyze by mass spectrometry to identify modifications

  • Compare modification patterns under different cellular conditions

• Functional consequences:

  • Design experiments to correlate modifications with VPS4 ATPase activity

  • Examine effects on oligomerization, which is critical for function

  • Investigate impacts on protein-protein interactions, particularly with ESCRT-III components

How can I adapt immunofluorescence protocols to study VPS4 dynamics during specific cellular processes like cytokinesis?

To study VPS4 dynamics during cytokinesis:

• Cell synchronization:

  • Synchronize cells using thymidine block, nocodazole, or other methods

  • Release and collect cells at different cytokinesis stages

• Dual immunostaining protocols:

  • Co-stain for VPS4 and cytokinesis markers (e.g., Aurora B, MKLP1, or midbody markers)

  • Include CHMP4C and ZFYVE19/ANCHR staining, as these proteins retain VPS4 at the midbody

• Live-cell imaging optimization:

  • Use fluorescently tagged VPS4 constructs for live imaging

  • Employ fast acquisition settings to capture dynamic events

  • Consider photobleaching approaches (FRAP) to measure VPS4 turnover at the midbody

• Super-resolution microscopy:

  • Apply techniques like STED or STORM for precise localization

  • Focus on the midbody region for detailed analysis of VPS4 positioning

• Temporal correlation with abscission:

  • Monitor VPS4 release from the midbody in relation to abscission timing

  • Track dephosphorylation events of CHMP4C which trigger VPS4 release

• Specific inhibitor treatments:

  • Use Aurora B inhibitors to disrupt abscission checkpoint signaling

  • Assess effects on VPS4 recruitment and release dynamics

• Experimental controls:

  • Include VPS4 dominant-negative mutants as controls for abscission defects

  • Use siRNA depletion of VPS4 interactors to determine dependency relationships